.jpeg)
{{ variable.name }}
Enrectinib is a tyrosine kinase inhibitor that can inhibit the protein activity related to NTRK1/2/3, ROS1 and ALK gene fusion, thereby inhibiting the proliferation of tumor cells.
Enrectinib is an inhibitor that targets neurotrophic tyrosine receptor kinase (NTRK) and ROS1. It is suitable for:
1. NTRK gene fusion-positive solid tumors :
The treatment of NTRK gene fusion-positive solid tumors in children and adult patients over 1 month old must be confirmed by testing approved by the FDA.
Applicable to metastasis or cases where surgical resection may lead to serious complications, and there is progression after treatment or there is no satisfactory alternative therapy.
2. ROS1-positive non-small cell lung cancer :
For adult patients with ROS1-positive metastatic non-small cell lung cancer.
1. Dosage form :
Oral dosage.
2. Recommended dosage of :
Adults and children (body surface area ≥ 1.5m²): 600mg once a day.
Children (body surface area <1.5m²): Adjust dose according to body weight, once daily.
3. Precautions :
Can be taken on an empty stomach or with food.
When you miss a dose, you can take it again if it is ≥ 12 hours before the next dose; there is no need to take it again after vomiting.
1. Common adverse reactions :
Fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, abnormal sensation, dyspnea, etc.
2. Serious risks :
Congestive heart failure : Heart function needs to be monitored, and the drug should be suspended or permanently discontinued when symptoms occur.
Central nervous system effects : May cause cognitive impairment, mood changes, or dizziness.
Hepatotoxicity : Liver function needs to be monitored regularly. Medication should be suspended when ALT/AST increases ≥3 times.
Fracture risk : Long-term use may increase the probability of fracture.
1. Contraindications : It is prohibited for those who are allergic to entrectinib or excipients.
2. Monitoring requirements :
Check heart function, liver function and electrolytes regularly before and during treatment.
Pediatric patients need to monitor their growth and development.
3. Drug interactions :
Avoid the combined use of strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin).
4. Special groups :
Contraindicated for pregnant women (may cause harm to the fetus). Medication or breastfeeding needs to be discontinued during lactation.
Elderly patients do not need to adjust the dosage, but they need to be closely monitored for adverse reactions.
Store away from light at 20°C-25°C (short-term fluctuations of 15°C-30°C are allowed).
Oral granules should be kept dry and protected from moisture.